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Estimates of the number of adults and children living with 
HIV/AIDS in South Africa range between 3.81 and 5.3 million 
individuals.2  The annual national antenatal surveillance 
survey in 20033 revealed an HIV prevalence rate in the adult 
population of 27.9%, a figure that has risen steadily for over a 
decade. Substantial differences in HIV prevalence have been 
documented across the provinces, with KwaZulu-Natal having 
the highest prevalence at 37.5% and the Western Cape the 
lowest rate at 13.1%.3 Using the Metropolitan-Doyle model4 it is 
estimated that the annual number of AIDS deaths will increase 
from 120 000 to between 545 000 and 635 000 between 2000 and 
2010. 
   South Africa is therefore experiencing an HIV/AIDS 
epidemic of enormous proportions, and like all the other 
sectors the workplace will be adversely affected. In fact it is 
estimated that the HIV/AIDS epidemic will cost South Africa 
17% in GDP growth by 2010.5 This epidemic has forced the 
business sector to reconsider its role in disease prevention and 
management.
   Antenatal HIV survey data may be severely limited when 
extrapolated to estimate prevalence in the general population 
or large workforces. Data on children and the elderly, who 
are at substantially lower risk of HIV, are not captured by 
antenatal surveys. With regard to adults in sexually active age 
groups, the antenatal survey prevalence figures do not reflect 
the lower overall risk for men, people who are less sexually 
active, and communities accessing private sector facilities. 
Some studies6,7 indicate that fertility among HIV-positive 
women is substantially lower than among uninfected women, 
and this suggests that antenatal data may in fact underestimate 
HIV prevalence in women of reproductive age in many 
communities. A systematically sampled national household 
HIV prevalence survey conducted in 20028 estimated the HIV 
prevalence rate in the general South African population to be 
11.4%. 
   Other studies investigating HIV prevalence in companies 
and communities have demonstrated large differences in 
prevalence within provinces, and between social and racial 
groups.9 In an attempt to determine the costs of HIV/AIDS to 
business in southern Africa Rosen and colleagues10 surveyed 
6 formal-sector enterprises in South Africa and Botswana.  
Organisations provided detailed company-specific data on 
employees, costs and estimated HIV prevalence. Using a 
9-year median survival time, the undiscounted costs as a 
percentage of payrolls were calculated as 4.8% for agribusiness, 
12.2 - 18.1% for mining and 1.8% for retail respectively.  
Similar studies in Kenya, Botswana, Zimbabwe, Malawi and 
South Africa have found that increased employee benefit 
claims, increased absenteeism, and increased expenditures 
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Objectives. To determine the HIV prevalence rate at Anglo 
Platinum, a large, multinational organisation operating in 
South Africa (Gauteng, Limpopo and North-West), and to 
assess the merits, methodology and outcomes of the survey.
Methods. A sample of 11 339 individuals, representing 18.4% 
of the organisation’s employees, were tested for HIV. HIV 
prevalence was determined using the Wellcozyme HIV 1+2 
GACELISA test (oral fluid assay), and variables such as age, 
site, grade and gender were analysed.   
Results. The overall prevalence rate was 24.6% (95% confidence 
interval (CI): 20.4 - 28.8), translating into approximately 15 167 
HIV-infected individuals. Interestingly, there was considerable 
variation in prevalence between sites within the same 
geographical regions, highlighting the limitations of using 
data obtained from antenatal HIV surveillance surveys. As an 
example, the prevalence at sites in Limpopo province ranged 
from 9.8% to 19%, with the same basic demographic data in 
terms of race, age and gender.
Conclusion. The survey data enabled the organisation to 
plan resource allocation appropriately for each business unit 
following their commitment to the treatment of infected 
employees with antiretroviral therapy.  These baseline 
prevalence data also provide an opportunity for monitoring 
of proposed interventions using cross-sectional surveys at 
designated intervals in the future. 
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on recruitment and training are among the highest HIV-
related costs faced by companies.10 Evian and colleagues11 
demonstrated an average HIV prevalence rate of 16% on data 
accumulated from 34 workforces, totalling 44 000 employees, in 
South Africa. Prior investigation by Corbett and colleagues of  
1 773 mineworkers revealed an HIV prevalence rate of 27%.12
   The role of HIV testing in the workplace has been the centre 
of much controversy in South Africa. Although the Employ- 
ment Equity Act (No. 55 of 1998) prohibits employers from 
conducting pre-employment HIV testing without labour court 
permission,13 the value of anonymous, unlinked prevalence 
testing as part of a workplace programme is not clear. This 
article presents the findings and lessons learned during a 
prevalence survey conducted at Anglo Platinum, a large, 
multinational organisa- tion operating in South Africa and 
employing over 50 000 people.  
Methods
Company preparation
Essential to ensuring a successful prevalence survey is the 
preparation phase conducted by the company. In this regard 
the following was done: (i) all major work force unions were 
consulted and the rationale for the prevalence survey was well 
explained; (ii) labour court consultation was undertaken; (iii) 
communication regarding the survey was carried out by each 
respective business unit, communication packs were provided 
and briefing sessions were held for the communication experts 
and HIV co-ordinators for each business unit; (iv) confiden- 
tiality agreements were signed by the organisation conducting 
the testing and Anglo Platinum; and (v) ethics approval was 
obtained from the University of the Witwatersrand (ethics 
number 001109).
   Each business area within each site at Anglo Platinum was 
responsible for conducting its own awareness programme 
before the testing dates. This entailed explaining that the 
testing was voluntary and anonymous, and the underlying 
rationale for the testing. Designated HIV/AIDS co-ordinators 
at Anglo Platinum were briefed before the testing and trained 
to assist in sample collection.
Study population 
Eleven thousand three hundred and thirty-nine respondents 
from Anglo Platinum participated in the HIV prevalence 
testing, representing a sample of 18.4% of the total employees 
(including contractors) working at the mine. Participation was 
voluntary and samples were collected at the respective sites 
during the period 22 October - 29 November 2002.  
Sampling methods
Stratified random sampling was used across the organisation, 
with stratification by subgroup, site and grade. Because of the 
large sample size, age was not targeted as a necessary category 
to be considered for sample selection, but was recorded and 
checked against the population for representation.
   A 100% response rate from the entire organisation is 
obviously preferable, as it also serves the purpose of creating 
awareness during participation. This can be prohibitively 
expensive and often very little additional information is 
obtained by surveying the entire population. Because of the 
stigma associated with HIV/AIDS, added to the fact that 
people who know their status may not participate, a non-
response bias may be present if anything less than 100% is 
obtained. However, from the outset one can create a target 
sample group, for example an entire shift. 
   It may also be necessary to oversample certain categories; for 
example, more employees in upper income grades may know 
their HIV status and as such they may not participate readily. 
Oversampling may also be necessary when reporting back 
on a smaller business unit in order to keep the participants 
anonymous.  Further oversampling may be necessary to ensure 
that smaller demographic groups are sufficiently represented 
albeit at the expense of oversampling on larger demographic 
groups. Because of the necessity of oversampling in certain 
instances it is essential to weight the result accordingly from 
the raw data, taking into account the size of the sample at 
each site where testing took place. This is done because the 
proportion of employees from each level participating in the 
study does not exactly reflect the proportion of employees 
from each level (and site) working on the mine. 
Study procedures
Laboratory test methodology 
Previously prevalence testing was done with conventional 
blood-based HIV enzyme-linked immunorsorbent assays 
(ELISAs) using rapid testing strategies or central laboratory-
based confirmation. The fieldwork is generally arduous and 
time consuming since staff must have phlebotomy skills. In 
addition, because of the invasive nature of the process there 
is often reluctance on the part of potential participants to 
come forward for testing in the survey.  Several studies in the 
literature confirm that individuals prefer the use of rapid, non-
invasive assays.14 For these reasons oral fluid collection was 
selected as the methodology of choice for the study. 
   Whole saliva, glandular-duct saliva, or mucosal transudates 
are specimens that can be collected for tests to detect antibody 
to HIV in oral secretions. Oral fluid is a complex mixture of 
salivary gland secretions, gingival crevicular fluid, bacteria 
and particulate matter. There are several approaches to 
conducting this type of testing, two of which have been used 
for surveillance in the South African setting: (i) collection of 
oral fluid with a device called OraSure (OraSure Technologies, 
Pennsylvania), and testing of this sample using the Vironostika 
Uniform II HIV-1/2 ELISA assay (Biomerieux, Boxtel, 
Netherlands), which is a Food and Drug Administration 
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(FDA)-approved testing combination;15 or (ii) collection of 
whole saliva without a device and use of the Wellcozyme 
HIV 1+2 GACELISA test (Abbott). The latter was selected 
for reasons of cost, population preference and to speed up 
the collection process since the Orasure collection device 
requires several minutes to complete collection. The sensitivity 
and specificity of the GACELISA on saliva samples has 
been evaluated previously in a number of studies16-23 and is 
estimated to be in the region of 96.9 - 100% and 99.8 - 100% 
respectively. These reported sensitivities and specificities 
compare well with those of serum-based assays and qualify 
oral fluid for the screening of HIV infection in both high- and 
low-risk populations. It should be noted that the GACELISA 
is no longer commercially available and has been withdrawn 
by the supplier since the conduct of this study for financial 
reasons.
Procedure for sample collection 
A minimum of 0.5 ml of oral fluid was required for the testing 
strategy. A bar-coded sticker was affixed to each sample bottle; 
the sample collector recorded the age, employment grade, 
gender and site code on the relevant sticker. The samples were 
then transported to the CLS Serology Laboratory on a daily 
basis. The samples were placed in a freezer at the laboratory at 
the University of the Witwatersrand Medical School where they 
were frozen and stored at –15 - −25°C. Once ready for testing 
the relevant samples were thawed and then tested according to 
the manufacturer’s instructions.
Data capture and statistical analysis
The results from each participant were recorded and analysed 
using Excel and a statistical processing package called Number 
Crunching Statistical Software (NCSS). The following variables 
were captured for analysis: test result, age, site, grade and 
gender. For purposes of the study the variable ‘grade’ was split 
into four broad bands, namely ‘contractor’ (any contractor on 
site), ‘upper’, consisting of executive and upper management, 
‘middle’, consisting of middle management and skilled 
artisans, and ‘lower’, consisting of the remainder of the less-
skilled workforce.  A fifth category was used to record data for 
trainee staff and bursary students. 
   Significant steps were taken to ensure quality assurance 
of the data: (i) 20% of the total study data captured were 
reinvestigated for data-capture errors by referring to the 
original results from the medical laboratory; and (ii) frequency 
counts for each of the variables investigated, and minima and 
maxima for interval or ratio level data, were generated in order 
to ensure that no values were missing, that no values had 
been entered incorrectly, and that there were no obvious and 
inexplicable outliers. 
   It is obvious that the results are highly dependent on 
demographic subgroups. A logistical regression analysis 
was performed to ensure that the correct weighting per 
demographic subgroup was used on the raw data to correct for 
any possible over- or undersampling and the best estimated 
prevalence per site was calculated based on the population 
versus the sample taken. This best estimate of prevalence per 
site was then further weighted correctly per geographical 
region to obtain an overall company HIV prevalence rate. 
Geographical criteria were used as this seems to be the most 
defining factor regarding HIV prevalence throughout South 
Africa, barring race which was not recorded. 
Results
Response rate
The response rate at each site was investigated and revealed no 
more than 5 refusals per site. Only 1 site (A4) had a noticeably 
poor response rate. An overall value could not be reported 
since each site was investigated separately. This is discussed 
further in the text.
Prevalence results before implementation of 
weighting strategy
The results are depicted as bar charts in Figs 1 - 3. The bar 
charts present the data as the number of positive individuals 
out of the total number of samples tested, and also reflect 
this as a percentage value. The demographic subgroups 
investigated were region, age and employment grade. 
Weighted HIV prevalence by site
The HIV prevalence rate at Anglo Platinum was estimated by 
combining the individual best-estimated HIV prevalence for 
each site and then making a weighted overall estimate (Table I). 
The estimate of each site was also weighted accordingly. This 
was done to correct any potential over- and undersampling, 
Fig. 1. Number of HIV-positive samples identified within each 
region. The percentage of positive individuals is shown on each bar. 
Site A4 should be read with caution as a strong element of non-
response bias was suspected.
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and correctly apportions the sample to the population 
demographic characteristics. Even though an entire shift was 
targeted and very little non-participation was experienced 
owing to the fact that HIV prevalence testing was voluntary, 
it is still often necessary to oversample to ensure that a spread 
of demographics is obtained. These data are also presented in 
bar-chart format in Fig. 4, including the antenatal clinic data for 
each region.3 
   The overall estimate of HIV prevalence for the mine was 
therefore calculated as 24.6%. Since this estimate is based on 
a specific sample size, lower and upper confidence limits can 
be calculated such that there is a 95% chance that the true 
proportion of HIV-positive employees lies between those 
confidence limits. In this study the lower confidence limit was 
20.4% and the upper limit 28.8%. Table I also represents each 
business unit separately with its respective confidence limits. 
As an example, at site A2 the measured prevalence was 24.5%, 
which means that an estimated 2 748 employees of the total  
11 211 employees at this site were HIV-positive. Using the 
confidence limits as presented, we are therefore 95% certain 
that A2 has between 2 366 and 3 131 HIV-positive employees.
Discussion
Several interesting observations emerged during the course 
of this prevalence survey.  As demonstrated in Table I, the 
overall estimate of HIV prevalence for the mine was 24.6% 
(95% confidence interval (CI): 20.4, 28.8), which meant that 
approximately 15 167 employees were HIV-positive at the 
time of sampling. These results have ensured that appropriate 
information was available for accurate costing and planning 
models, thus providing Anglo Platinum with invaluable 
data on expected trends relating to number of HIV-positive 
employees, AIDS-sick employees and AIDS deaths. Given 
Anglo Platinum’s commitment to the treatment of infected 
employees with antiretroviral therapy, the future cost 
implications can be estimated with a degree of accuracy. In 
addition, this provides a further platform for the investigation 
of different risk groups that may require specific interventions. 
As mentioned above these numbers differed per business 
unit and the costing model allows each business unit to plan 
independently. 
   These baseline prevalence data also provide an opportunity 
for monitoring of proposed interventions using repeat 
Fig. 2. Number of HIV-positive individuals by age distribution. The 
percentages per group are shown on the bars.
Fig. 3. Number of HIV-positive individuals by employment grade.
Fig. 4. Antenatal HIV survey prevalence values compared with 
Anglo Platinum prevalence values for the regions. 
Table I. Weighted HIV prevalence data by site/ region
  % estimated HIV-  
Region Site positive (95% CI) Sample size
Gauteng A1 7.8% (5.4, 10.3)     848
North-West A2 24.5% (22.1, 27.9)  11 211
North-West A3 27.7% (23.2, 32.1)  3 976
North-West A4 9.3% (6.0, 14.6)*     529
North-West A5 17.3% (14.5, 20.1)  1 928
North-West A6 28.1% (23.5, 32.8) 27 900
North-West A7 22.8% (18.5, 27.1)  8 496
Limpopo A8 16.5% (12.8, 20.2)  1 640
Limpopo A9 9.8% (5.4, 14.2)     164
Limpopo A10 19.0% (16.1, 22.4)  2 942
Limpopo A11 12.3% (7.2, 17.4)  1 930
Group   24.6% (20.4, 28.8) 61 564
*Site A4 should be read with caution as a strong element of non-response bias was 
suspected.
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cross-sectional surveys at designated intervals in the HIV 
management programme. A study conducted on workplace 
programmes in South Africa in 1995 revealed that few 
organisations ever conducted formal evaluations of their 
interventions.24
   As expected, it was observed that prevalence by age (Fig. 2) 
was highest in the 30 - 39-year age group (approximately 25%). 
This is in contrast to the national antenatal clinic prevalence 
data from 20033 which show consistently different prevalence 
rates, with the 25 - 29-year age category showing the highest 
prevalence at 35.4%.  The lowest prevalence in this mining 
population appeared to be in the 18 - 24-year age group (12%). 
The Human Sciences Research Council (HSRC) data report the 
rate among males in the 18 - 24-year age group to be 7%, also 
the lowest when compared with these relevant age groups.8 
The above results may suggest that there is an effective 
induction and education programme in place for staff. The 
future challenge will be to maintain this trend as employees 
move into the higher age categories and to keep new recruits 
well educated, with the aim of lowering this percentage further.
   Different sites were chosen in order to obtain a representative 
sample (prior prevalence surveys indicated differences between 
different business areas (sites) even though geographically 
the sites wore in close proximity to each other). There was 
considerable variation in prevalence between sites in the 
same geographical region (Table I). To quote an example, the 
prevalence in Limpopo Province ranged from 9.8% to 19% 
(sites A9 - A11), with the same basic demographic data. A 
similar picture was observed for North-West province (sites 
A2 - A7), where HIV prevalence ranged between 16% and 27% 
(site A4 was excluded here because of suspected non-response 
bias). Further research is therefore needed to try to delineate 
specific reasons for the differences observed between sites 
that are often no more than 10 km apart. Possible factors to 
be explored are the intervention programmes of individual 
mining sites, staff recruitment policies, sexual behaviour 
patterns and ethnic differences. 
   The key factor in a successful prevalence survey appears 
to be participation of all stakeholders, as was observed in 
this study. During the course of the process the following 
qualitative factors appeared to influence success: (i) upfront 
awareness as to why the prevalence survey was being done; 
(ii) the fact that the survey was conducted by an outside 
independent organisation; (iii) participant awareness that 
company management would not have access to the raw 
data and that the organisation conducting the survey would 
report back in a way that eliminated disclosure of any smaller 
demographic grouping and that avoided discrimination against 
any particular group; and (iv) the choice of non-invasive saliva-
based assay for HIV testing.
   Non-response bias is introduced into a sample when 
potential participants are free to decide whether or not they 
would like to participate in a study, and their choice is likely 
to be influenced by some feature of the study itself. This 
creates the possibility that those respondents who participate 
willingly could differ systematically from those who choose 
not to participate. In this study it was found that many lower-
income grade employees participating at the start or end of an 
underground shift agreed to participate if the first person in 
the shift (or the shift boss) agreed to participate, and refused 
participation when that person refused participation. This is 
likely to have reduced non-response bias because only the first 
person in the queue (or in some cases the shift boss) made 
the conscious decision to participate or not participate based 
on his/her HIV status or orientation towards HIV prevalence 
testing. The other members of the group did not make a 
conscious decision based on knowledge of HIV status or any 
other obvious variable. Thus the non-response bias was limited 
to a small percentage of the sample. The large sample size and 
the relatively small proportion of individuals who were aware 
of their HIV status also mitigated against the biases described 
above.
   On the other hand, employees in higher-income grades 
and in more general business services tended to make their 
decision to participate or not on their own, and therefore 
the impact of non-response bias was potentially greater. As 
expected, significant differences were noted in the prevalence 
statistics when separation was done by employment grade. The 
highest prevalence was in the lower-income grades and among 
contractors at prevalence levels of 24% and 22% respectively 
among those tested. The remaining income grades (middle 
and upper) showed 13% and 6% prevalence rates respectively 
among those tested.
   A positive outcome of prevalence surveys is the awareness 
created among the employees. One particular business unit 
worth mentioning was a small unit where close to 100% of the 
staff participated owing to strong management leadership. 
Information on the treatment programme provided by Anglo 
Platinum and voluntary counselling and testing (VCT) for staff 
(provided by an independent service provider) were offered 
on site at the feedback session. Employees were encouraged to 
use this service on the day. The uptake (on site) was extremely 
positive, encouraging further on-site VCT. The awareness 
created by a prevalence survey may therefore assist in the 
uptake of VCT services in the workplace.
   This study serves to highlight the fact that although models 
based on antenatal surveillance or insurance modelling give 
some sort of indication of HIV prevalence, they are not useful 
for the implementation of an HIV management programme 
within an organisation at a micro level. The study also 
demonstrates that a substantial amount of information can 
be generated from prevalence surveys to assist and monitor 
ongoing workplace programmes. However antenatal clinic 
data are useful on a macro level in predicting the extent of HIV 
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prevalence in terms of geographical location while making 
adjustments for age, gender, and income/education level 
(private versus public health). 
   The authors gratefully acknowledge the staff at Anglo Platinum 
who participated in the study.
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